Helix Acquisition Corp. Overview
Pro stress-test →Helix Acquisition Corp. (HLXA) was a special purpose acquisition company (SPAC) that completed its business combination with MoonLake Immunotherapeutics in April 2022 and is no longer an active SPAC vehicle. The original HLXA entity now operates as MoonLake Immunotherapeutics, a clinical-stage biotechnology company.
Strategic Profile
Pro stress-test →As a historical SPAC, Helix Acquisition was sponsored by Cormorant Asset Management and focused on healthcare sector targets. The vehicle successfully deployed capital into immunotherapy, though it is now defunct as a standalone acquisition entity.
Competitive Landscape
Pro stress-test →As a dissolved SPAC, Helix Acquisition Corp. has no current competitive positioning. Its merger partner, MoonLake Immunotherapeutics, now competes in the clinical-stage immunotherapy space.
Industry Context
Helix Acquisition Corp. operates in Special Purpose Acquisition Companies (SPACs).
Key facts
Founded: 2020 · Headquarters: Boston, MA · Employees: N/A · Revenue: N/A · Market cap: N/A